Fibroscan ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
93原発性胆汁性胆管炎1
171ウィルソン病1

93. 原発性胆汁性胆管炎


臨床試験数 : 282 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02931513
(ClinicalTrials.gov)
September 201611/10/2016sCD163 in PBC Patients - Assessment of Treatment ResponseMacrophage Activation Marker sCD163 in PBC Patients - Assessment of Treatment Response to UDCAPrimary Biliary Cirrhosis;Liver Inflammation;Ursodeoxycholic AcidOther: Blood samples;Device: Fibroscan;Other: Questionnaires;Biological: Liver biopsyUniversity of AarhusNULLRecruiting18 YearsN/AAll40Denmark

171. ウィルソン病


臨床試験数 : 68 薬物数 : 79 - (DrugBank : 17) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 28
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02702765
(ClinicalTrials.gov)
February 201626/2/2016sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and FibrosisMacrophages and the Macrophage Activation Markers sCD163 and Mannose Receptor (sMR) in Patients With Wilsons Disease - Associations With Liver Disease Severity and FibrosisWilsons DiseaseProcedure: Fibroscan;Procedure: Ultrasound;Drug: Galactose;Procedure: Liver biopsy;Procedure: Functional hepatic nitrogen clearanceUniversity of AarhusAarhus University HospitalActive, not recruiting18 Years100 YearsAll33N/ADenmark